SAN RAMON, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical
company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral
delivery needs, today announced that Jonathan M. N. Rigby, President and Chief Executive Officer, is scheduled to present at the
2017 Wedbush PacGrow Healthcare Conference in New York, NY on Wednesday, August 16, 2017 at 9:10 a.m. EDT. Management will
also be available for one-on-one meetings at the conference.
A webcast of the Company’s presentation will be available on the investor relations section of SteadyMed’s
website at www.steadymed.com. A webcast replay of the presentation will be available for 90 days.
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan
and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development
stage drug product that combines SteadyMed's pre-filled, sterile, single use, disposable, PatchPump® infusion system, with
treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to
commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the
commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot,
Israel. For additional information about SteadyMed please visit www.steadymed.com.
Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 mrigby@steadymed.com The Ruth Group Lee Roth (646) 536-7012 lroth@theruthgroup.com